Thomas Yau
Chinese University of Hong Kong(HK)Queen Mary Hospital(CN)University of Hong Kong(HK)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies, Cholangiocarcinoma and Gallbladder Cancer Studies
Most-Cited Works
- → Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial(2017)4,261 cited
- → Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial(2019)1,782 cited
- → Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma(2022)1,332 cited
- → Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib(2020)1,179 cited
- → Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial(2023)936 cited
- → Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial